TheTechno Optimist.

DexterDistalmotion—Johnson & Johnson's venture arm makes a strategic investment in DistalmotionDexterDistalmotion—Dexter cleared by FDA for ventral hernia repair, its fifth US indicationDexterDistalmotion—Distalmotion raises $150M Series G led by Revival Healthcare Capital; Chas McKhann named executive chairman

Dexter

by DistalmotionCHUS

Bring robotic keyhole surgery to the outpatient centres where most routine operations now happen. Big robots are too costly and bulky for them; a cheaper, mobile one could give everyday hernia and gallbladder patients robotic precision.

DeployStage 4 of 5

FDA-cleared for five outpatient procedures; 4,000+ patients; pushing into US ambulatory surgery centres.

Updated 13 Aug 2026Checked 11 Oct0 updates this week

Milestones

Next · Scale-up in US ambulatory surgery centres
  1. Dexter in routine clinical use in Europe2023Complete.
  2. $150M Series F led by Revival Healthcare CapitalApr 2023Complete.
  3. FDA De Novo authorisation (inguinal hernia repair)28 Oct 2024Complete.
  4. First US patients treated, outpatient settingDec 2024Complete.
  5. First US sale (Memorial Hermann)25 Mar 2025Complete.
  6. FDA clearance: gallbladder removal28 May 2025Complete.
  7. FDA clearance: benign hysterectomy1 Oct 2025Complete.
  8. FDA clearance: sacrocolpopexy (gynecology)16 Jun 2026Complete.
  9. FDA clearance: ventral hernia repair13 Aug 2026Complete.
  10. Scale-up in US ambulatory surgery centresTarget 2026Current milestone.

Most important updates

Upcoming

  1. 2026Scale-up in US ambulatory surgery centres (next)
Primer